Azelis Group N.V.

AZE

Equity

ISIN BE0974400328 / Valor 113722477

Euronext - Euronext Brussels (2026-06-02)

EUR 10.37+1.67%

Azelis Group N.V.
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Azelis Group N.V. is a leading global distributor of specialty chemicals and food ingredients, serving a wide range of industries including personal care, pharmaceuticals, food and beverage, and industrial chemicals. The company operates through a comprehensive network of suppliers and customers, providing value-added services such as formulation development, technical support, and regulatory guidance. Azelis leverages its extensive market knowledge and technical expertise to deliver innovative solutions tailored to the specific needs of its clients. The company also offers a digital customer portal that facilitates seamless interaction with its offerings, allowing users to access trends, order samples, request quotes, and manage product reorders efficiently. With a strong focus on innovation and customer service, Azelis continues to expand its global footprint and enhance its position as a key player in the specialty chemicals distribution sector.

Summarized from source with an LLMView SourceSector: Industrials

Revenue detail

Group revenue: €1,041m in Q1 2026. Organic sales fell 3.9%, acquisitions added 3.3%, and FX translated to a c.4.5% headwind, producing a reported decline of 5.2% year‑on‑year.

Profitability

Gross profit €246m (23.7% margin, -38 bps) driven by negative mix effects (notably in APAC). Adjusted EBITA €104m with a 10.0% margin (-86 bps). Conversion margin (EBITA-to-gross-profit) declined to 42.4%.

Cash generation & working capital

Free cash flow €119m with a free cash flow conversion ratio of c.113% (112.7% reported). Net working capital/Sales improved to 13.9% (down from 14.7% year‑on‑year and 14.1% at Dec‑25).

Balance sheet & leverage

Net debt approximately €1.5bn (reduced for the second consecutive quarter on a reported basis) and leverage at 3.4x. Available liquidity (cash + undrawn RCF) about €799m at quarter end.

Regional performance

APAC: organic revenue +4.0% (reported down 4.8% due to FX), but margin pressure from negative mix (GP margin 19.3%). EMEA: weaker organic trends (-9.5% organic) partially offset by acquisitions. Americas: broadly stable in constant currency, with reported weakness from FX.

Segments

Life Sciences: €662m (stable in constant currency, acquisitions up c.4.6% contribution). Industrial Chemicals: €379m, down modestly in constant currency; organic weakness partly offset by acquisitions.

Outlook & management focus

Azelis warns of continued market volatility due to geopolitical tensions and expects any near‑term uplift to be more moderate than post‑COVID pre‑buying. The Group’s priorities are disciplined cost control, working capital optimisation and cash generation to navigate the recovery.

Summarized from source with an LLMView Source

Key figures

-27.9%1Y

-56.7%3Y

%5Y

Performance

37.8%1Y

36.3%3Y

36.1%5Y

Volatility